Development of novel medication strategy and drug efficacy on monocyte lineage cells of a JAK3 inhibitor in rheumatoid arthritis patients

为了评估jak3抑制剂cp690,550 （CP）对类风湿关节炎患者的影响，我们将重点放在单核细胞谱系细胞上，单核细胞谱系细胞是骨吸收所必需的破骨细胞的祖细胞，树突状细胞（dc）是免疫反应的起点。破骨细胞和树突细胞的分化不受CP的影响，破骨细胞的骨吸收也不受CP的影响。然而，共刺激分子在dc上的表达被抑制，淋巴细胞的共培养导致淋巴细胞增殖和IFN-g的产生受到抑制。

In order to evaluate the effect of a Jak3-inhibitor CP690, 550(CP) on rheumatoid arthritis patients, we have focused on monocyte lineage cells, a progenitor for osteoclasts essential for bone resorption and dendritic cells(DCs) that functions as a start point of immune reaction. Differentiation of osteoclasts and DCs were not affected by the addition of CP. Bone resorption of osteoclasts was not affected by CP as well. Although, expression of co-stimulatory molecules on DCs were suppressed and co-culture of lymphocytes resulted in suppressed lymphocyte proliferation and IFN-g production.